2. Neurological Disease

Neurological Disease

Neurological Disease

Related Products

PDF 88.0 MB

A range of neurological disorders, including epilepsy and dystonia, may involve dysfunctional intracortical inhibition, and may respond to treatments that modify it. Parkinson’s is a neurodegenerative disease characterized by increased activity of GABA in basal ganglia and the loss of dopamine in nigrostriatum, associated with rigidity, resting tremor, gait with accelerating steps, and fixed inexpressive face. Neurological deficits, along with neuromuscular involvement, are characteristic of mitochondrial disease, and these symptoms can have a dramatic impact on patient quality of life. Neurological features may be manifold, ranging from neural deafness, ataxia, peripheral neuropathy, migraine, seizures, stroke‐like episodes and dementia and depend on the part of the nervous system affected.

Cat. No. Product Name CAS No. Purity Chemical Structure
  • HY-402309
    IGF-1R modulator 1 2375424-89-6 98%
    IGF-1R modulator 1 (Example 5) is an IGF-1R modulator, with EC50s of 0.29 μM (FGFR1), 0.25 μM (IGF1R), 0.34 μM (TrkA), 0.39 μM (TrkB). IGF-1R modulator 1 can be used for research of diseases characterised by impaired signalling of neurotrophins and/or other trophic factors, such as Alzheimer's disease.
    IGF-1R modulator 1
  • HY-41700R
    D-Alanine (Standard) 338-69-2
    D-Alanine (Standard) is the analytical standard of D-Alanine. This product is intended for research and analytical applications. D-Alanine is a weak GlyR (inhibitory glycine receptor) and PMBA agonist, with an EC50 of 9 mM for GlyR.
    D-Alanine (Standard)
  • HY-44178S
    Diethyl butylmalonate-D9 1189865-34-6 98%
    Diethyl butylmalonate-d9 is the deuterium labeled Diethyl butylmalonate (HY-44178). Diethyl butylmalonate is a competitive inhibitor of succinate dehydrogenase. Diethyl butylmalonate exerts anti-inflammatory effects by inhibiting ROS production. Diethyl butylmalonate also has neuroprotective activity. In addition, Diethyl butylmalonate shows toxicity to T. pyriformis, with its log(IGC50-1) being 0.557. Diethyl butylmalonate can be used in the research of diseases such as Alzheimer's disease.
    Diethyl butylmalonate-D9
  • HY-50682A
    Azeliragon dihydrochloride 1284150-65-7 98%
    Azeliragon dihydrochloride (TTP488) is an orally bioavailable inhibitor of the receptor for advanced glycation end products (RAGE) in development as a potential treatment to slow disease progression in patients with mild Alzheimer’s disease (AD). Azeliragon dihydrochloride also can cross the blood-brain barrier (BBB).
    Azeliragon dihydrochloride
  • HY-50722A
    (Rac)-NNC 55-0396 2517420-92-5
    (Rac)-NNC 55-0396 is the racemate of NNC 55-0396 (HY-50722).
    (Rac)-NNC 55-0396
  • HY-69019A
    7-Nitroindazole sodium 161467-34-1 98%
    7-Nitroindazole sodium is a selective and BBB-penetrable inhibitor of nitric oxide synthase (NOS). 7-Nitroindazole sodium can inhibit the activity of central NOS with an IC50 of 0.47 μM in the cerebellum of mice. 7-Nitroindazole sodium has anti-injurious and neuroprotective properties.
    7-Nitroindazole sodium
  • HY-70059A
    (Rac)-LY341495
    (Rac)-LY341495 is the isomers of LY341495 (HY-70059) can be used as control compounds in experiments. LY341495 is a metabotropic glutamate receptor (mGluR) antagonist with IC50s of 21 nM, 14 nM, 7.8 μM, 8.2 μM, 170 nM, 990 nM, 22 μM for mGlu2, mGlu3, mGlu1a, mGlu5a, mGlu8, mGlu7, and mGlu4 receptors, respectively.
    (Rac)-LY341495
  • HY-76316R
    Bergaptol (Standard) 486-60-2
    Bergaptol (Standard) is the analytical standard of Bergaptol. This product is intended for research and analytical applications. Bergaptol is an inhibitor of debenzylation of the CYP3A4 enzyme with an IC50 of 24.92 μM. Recent studies have shown that it has anti-proliferative and anti-cancer properties.
    Bergaptol (Standard)
  • HY-90010R
    Tolterodine tartrate (Standard) 124937-52-6
    Tolterodine (tartrate) (Standard) is the analytical standard of Tolterodine (tartrate). This product is intended for research and analytical applications. Tolterodine Tartrate (Kabi-2234; PNU-200583E) is a potent muscarinic receptor antagonist and shows selectivity for the urinary bladder over salivary glands in vivo.
    Tolterodine tartrate (Standard)
  • HY-A0002R
    Solifenacin Succinate (Standard) 242478-38-2
    Solifenacin (Succinate) (Standard) is the analytical standard of Solifenacin (Succinate). This product is intended for research and analytical applications. Solifenacin Succinate (YM905) is a novel muscarinic receptor antagonist with pKis of 7.6, 6.9 and 8.0 for M1, M2 and M3 receptors, respectively.
    Solifenacin Succinate (Standard)
  • HY-A0002S
    Solifenacin-d5 succinate 98%
    Solifenacin-d5 (succinate) is deuterium labeled Solifenacin (Succinate). Solifenacin Succinate (YM905) is a novel muscarinic receptor antagonist with pKis of 7.6, 6.9 and 8.0 for M1, M2 and M3 receptors, respectively.
    Solifenacin-d5 succinate
  • HY-A0007R
    Rotigotine Hydrochloride (Standard) 125572-93-2
    Rotigotine (Hydrochloride) (Standard) is the analytical standard of Rotigotine (Hydrochloride). This product is intended for research and analytical applications. Rotigotine Hydrochloride (N-0923 Hydrochloride) is a full agonist of dopamine receptor, a partial agonist of the 5-HT1A receptor, and an antagonist of the α2B-adrenergic receptor, with Ki of 0.71 nM, 4-15 nM, and 83 nM for the dopamine D3 receptor and D2, D5, D4 receptors, and dopamine D1 receptor.
    Rotigotine Hydrochloride (Standard)
  • HY-A0007S
    Rotigotine-d7 hydrochloride 98%
    Rotigotine-d7 (hydrochloride) is the deuterium labeled Rotigotine(N-0923), which is a dopamine D2 and D3 receptor agonist.
    Rotigotine-d7 hydrochloride
  • HY-A0009R
    Galanthamine hydrobromide (Standard) 1953-04-4
    Galanthamine (hydrobromide) (Standard) is the analytical standard of Galanthamine (hydrobromide). This product is intended for research and analytical applications. Galanthamine hydrobromide (Galantamine hydrobromide) is a selective, reversible, competitive, alkaloid AChE inhibitor, with an IC50 of 0.35 µM. Galanthamine hydrobromide is a potent allosteric potentiating ligand (APL) of human α3β4, α4β2, α6β4 nicotinic receptors ( nAChRs). Galanthamine hydrobromide is developed for the research of Alzheimer's disease (AD).
    Galanthamine hydrobromide (Standard)
  • HY-A0009S
    Galanthamine-d3 hydrobromide 98%
    Galanthamine-d3 (hydrobromide) is deuterium labeled Galanthamine (hydrobromide). Galanthamine hydrobromide (Galantamine hydrobromide) is a selective, reversible, competitive, alkaloid AChE inhibitor, with an IC50 of 0.35 μM. Galanthamine hydrobromide is a potent allosteric potentiating ligand (APL) of human α3β4, α4β2, α6β4 nicotinic receptors ( nAChRs). Galanthamine hydrobromide is developed for the research of Alzheimer's disease (AD).
    Galanthamine-d3 hydrobromide
  • HY-A0012R
    Darifenacin hydrobromide (Standard) 133099-07-7
    Darifenacin (hydrobromide) (Standard) is the analytical standard of Darifenacin (hydrobromide). This product is intended for research and analytical applications. Darifenacin (hydrobromide) is a selective and orally active M3 muscarinic receptor (M3R) antagonist with a pKi of 8.9. Darifenacin (hydrobromide) binds >20-fold more specifically to M3R than to other muscarinic receptors. Darifenacin (hydrobromide) can be used in the study of urinary incontinence and other symptoms of overactive bladder. Darifenacin (hydrobromide) inhibits tumor growth in colorectal cancer cells and has anti-tumor effects.
    Darifenacin hydrobromide (Standard)
  • HY-A0014S
    Ramelteon-d5 1134159-63-9 98%
    Ramelteon-d5 is deuterium labeled Ramelteon. Ramelteon is a potent, highly selective, and orally active agonist of MT1/MT2 with Ki values of 14 and 112 pM, respectively. Ramelteon has the potential for the research of insomnia. Ramelteon consistently reduces sleep onset after long-term treatment, with no next-morning residual effects or rebound insomnia or withdrawal symptoms upon discontinuation.
    Ramelteon-d5
  • HY-A0024S
    Tolterodine-d14 hydrochloride 1217645-16-3 ≥99.0%
    Tolterodine-d14 (hydrochloride) is the deuterium labeled Tolterodine hydrochloride. Tolterodine hydrochloride is a potent muscarinic receptor antagonist.
    Tolterodine-d14 hydrochloride
  • HY-A0030R
    Fesoterodine fumarate (Standard) 286930-03-8
    Fesoterodine (fumarate) (Standard) is the analytical standard of Fesoterodine (fumarate). This product is intended for research and analytical applications. Fesoterodine Fumarate is an orally active, nonsubtype selective, competitive muscarinic receptor (mAChR) antagonist with pKi values of 8.0, 7.7, 7.4, 7.3, 7.5 for M1, M2, M3, M4, M5 receptors, respectively. Fesoterodine Fumarate is used for the overactive bladder (OAB).
    Fesoterodine fumarate (Standard)
  • HY-A0042R
    Rufinamide (Standard) 106308-44-5
    Rufinamide (Standard) is the analytical standard of Rufinamide (HY-A0042). This product is intended for research and analytical applications. Rufinamide (CGP 33101) is an orally active antiepileptic compound that inhibits Na+ current activation, inhibits neuronal hyperexcitability, and has anticonvulsant effects. Rufinamide is used in the study of Lennox-Gastaut syndrome.
    Rufinamide (Standard)
Cat. No. Product Name / Synonyms Application Reactivity